메뉴 건너뛰기
Congenital Heart Disease
Volumn 5, Issue 2, 2010, Pages 165-167
Recurrent Exacerbations of Protein-losing Enteropathy after Initiation of Growth Hormone Therapy in a Fontan Patient Controlled with Spironolactone
Author keywords

Fontan Procedure; Growth Hormone; Protein Losing Enteropathy; Spironolactone
Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; CORTICOSTEROID; FUROSEMIDE; GROWTH HORMONE; HEPARIN; HYDROCHLOROTHIAZIDE; SPIRONOLACTONE;
EID: 77954369046     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2009.00320.x     Document Type: Article
Times cited : (11)
References (7)
  • 1
    • 0031955639 scopus 로고    scopus 로고
    • Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group
    • Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998, 115:1063-1073.
    • (1998) J Thorac Cardiovasc Surg , vol.115 , pp. 1063-1073
    • Mertens, L.1    Hagler, D.J.2    Sauer, U.3    Somerville, J.4    Gewillig, M.5
  • 2
    • 33746104483 scopus 로고    scopus 로고
    • Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms
    • Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 2006, 82:695-701.
    • (2006) Ann Thorac Surg , vol.82 , pp. 695-701
    • Ostrow, A.M.1    Freeze, H.2    Rychik, J.3
  • 4
    • 0037446188 scopus 로고    scopus 로고
    • Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease
    • Ringel RE, Peddy SB. Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol 2003, 91:1031-1032.
    • (2003) Am J Cardiol , vol.91 , pp. 1031-1032
    • Ringel, R.E.1    Peddy, S.B.2
  • 5
    • 33746558934 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker
    • Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006, 1:256-262.
    • (2006) Clin J Am Soc Nephrol , vol.1 , pp. 256-262
    • Chrysostomou, A.1    Pedagogos, E.2    MacGregor, L.3    Becker, G.J.4
  • 6
    • 0034279973 scopus 로고    scopus 로고
    • Somatic growth failure after the Fontan operation
    • Cohen MI, Bush DM, Ferry RJ. Somatic growth failure after the Fontan operation. Cardiol Young 2000, 10:447-457.
    • (2000) Cardiol Young , vol.10 , pp. 447-457
    • Cohen, M.I.1    Bush, D.M.2    Ferry, R.J.3
  • 7
    • 0031010273 scopus 로고    scopus 로고
    • Blockage of the rennin-angiotensin-aldosterone system prevents growth hormone-induced fluid retention in humans
    • Endocrinol Metab 35
    • Moller J, Moller N, Frandsen E, Wolthers T, Jorgensen JOL, Christiansen JS. Blockage of the rennin-angiotensin-aldosterone system prevents growth hormone-induced fluid retention in humans. Am J Physiol 1997, 272:E803-E808. Endocrinol Metab 35
    • (1997) Am J Physiol , vol.272
    • Moller, J.1    Moller, N.2    Frandsen, E.3    Wolthers, T.4    Jorgensen, J.O.L.5    Christiansen, J.S.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.